Endo Health Solutions Inc (ENDP): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Endo Health Solutions ( ENDP) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 1.1%. By the end of trading, Endo Health Solutions fell $1.04 (-2.2%) to $45.54 on heavy volume. Throughout the day, 3,756,776 shares of Endo Health Solutions exchanged hands as compared to its average daily volume of 1,634,900 shares. The stock ranged in price between $43.82-$46.90 after having opened the day at $46.42 as compared to the previous trading day's close of $46.58. Other companies within the Health Care sector that declined today were: Mast Therapeutics ( MSTX), down 32.1%, Lannett Incorporated ( LCI), down 13.4%, Zalicus ( ZLCS), down 11.3% and Neostem ( NBS), down 9.6%.

Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. Endo Health Solutions has a market cap of $5.2 billion and is part of the drugs industry. Shares are up 73.1% year to date as of the close of trading on Thursday. Currently there are 8 analysts that rate Endo Health Solutions a buy, 7 analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Endo Health Solutions as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.

On the positive front, GW Pharmaceuticals PLC ADR ( GWPH), up 175.1%, Discovery Laboratories ( DSCO), up 37.1%, Pro-Dex ( PDEX), up 20.1% and InspireMD ( NSPR), up 18.8% , were all gainers within the health care sector with Alexion Pharmaceuticals ( ALXN) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Illumina Shares Spike on Strong Earnings, Upside Still Remains: Biotech Movers

Geron Shares Take a Dive After J&J Unit-Led Trial Falters; Endo Closes Higher: Biotech Movers

Top Ranking Democrat McCaskill Expands Probe into Opioid Crisis

Canadian Pharma Goes Before FDA Panel Wednesday on Tamper Resistant Opioid

3 Biotech Stocks on Readers' Minds